immunotherapy malaria hemorragic fever geovax vaccines zika aids/hiv hbv lassa lasv

GeoVax Labs. (GOVX-OTC) Reports Promising Results for Lassa Fever Vaccine

2 Minute Read

Promising Results Reported for GeoVax's Lassa Fever Vaccine

GeoVax_Logo_Clear_1.jpgGeoVax announced today a significant step forward in developing its vaccine candidate for protection against Lassa hemorrhagic fever virus (LASV). Efficacy testing in a murine challenge model (using a LASV reassortant) showed a single dose of the candidate vaccine, GEO-LM01, provided 100% protection to mice infected with a lethal dose of the challenge virus.

During testing, mice were given a single-dose vaccination of GEO-LM01 into muscle tissue, then infected with 1000 Plaque Forming Unit of the challenge virus by intracranial inoculation. All vaccinated mice survived while all unvaccinated mice died within one week of infection. Vaccinated animals produced a strong T cell immune response against LASV at 10 days post vaccination. The study was conducted at the Institute of Human Virology at the University of Maryland School of Medicine in Baltimore, with a repeat of the study confirming the findings.

A member of the Arenaviridae virus family, LASV causes severe and often fatal hemorrhagic illnesses in an overlapping region with Ebola virus (EBOV). Compared to the unpredictable epidemics of filoviruses such as EBOV, LASV is endemic in West Africa with an annual incidence of over 300,000, and leading to 5,000 to 10,000 deaths.

New study data suggests that the annual number of LASV cases may actually be meaningfully higher, with 3 million infections and 67,000 deaths (making upwards of 200 million individuals at risk). There are no treatments or vaccines available today to stem LASV epidemics, even though LASV kills more people in one year than the EBOV did in the last 41 years after its first epidemic in 1976 in West Africa.

GeoVax's GEO-LM01 uses the Company's proven MVA-VLP vaccine platform, which has been shown to be safe and to induce durable antibody and T cell responses in multiple human clinical trials for GeoVax’s prophylactic HIV vaccine. Using the same platform, a single dose of GeoVax’s Ebola vaccine has been shown to protect 100% of rhesus monkeys against death.

GeoVax is also developing vaccines against Sudan virus (SUDV) and Marburg virus (MARV), two other lethal filoviruses for which no effective vaccine currently exists. In addition to developing the four individual vaccines (EBOV, LASV, SUDV, MARV), the Company’s seeks to combine the vaccines into a single tetravalent vaccine to provide broad protection for individuals at-risk for these viruses.

Lassa fever has a greater human impact than any other hemorrhagic fever virus, except for dengue fever, and despite this clear need, no vaccine has yet entered human clinical trials. GeoVax is now ready for advanced preclinical testing, which could lead to initiation of human clinical trials.

For more information on GeoVax, please refer to our Executive Informational Overview (EIO), issued on June 15, 2017. This EIO is a 80-page report detailing GeoVax's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Download GeoVax Report 



Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.